Case Report

Painful Diabetic Peripheral Neuropathy Relieved with Use of Oral Topiramate

Authors: Kristina M. Kline, MD, Dana G. Carroll, PHARMD, Karen F. Malnar, RN, CTR, CCRC

Abstract

Diabetic peripheral neuropathy affects 5 to 50% of people with diabetes in the United States. It is a progressive disorder that results in a gradual decrease in peripheral sensation and eventually complete loss of sensation. Patients with diabetic peripheral neuropathy are challenging to treat because of intolerable adverse medication effects and the development of tolerance to medical treatment. We present the case of a patient with peripheral neuropathy that was unresponsive to usual therapies. She experienced significant relief with the administration of topiramate. Topiramate is an anticonvulsant that is gaining recognition in the treatment of patients with neuropathic pain syndromes.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Calissi PT, Jaber LA. Peripheral diabetic neuropathy: Current concepts in treatment. Ann Pharmacother 1995; 29: 769–777.
 
2. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 2000; 60: 1029–1052.
 
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
 
4. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38: 869–880.
 
5. Vaillancourt PD, Langevin HM. Painful peripheral neuropathies. Med Clin North Am 1999; 83: 627–642.
 
6. Bajwa ZH, Sami N, Warfield CA, Wootton J. Topiramate relieves refractory intercostal neuralgia. Neurology 1999; 52: 1917.
 
7. Rosenfeld WE. Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997; 19: 1294–1308.
 
8. Schneiderman JH. Topiramate: Pharmacokinetics and pharmacodynamics. Can J Neurol Sci 1998; 25: S3–S5.
 
9. Zvartau-Hind M, Din MU, Gilani A, Lisak RP, Khan OA. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000; 55: 1587–1588.
 
10. Potter D, Edwards R, Bennington VT. Potential role of topiramate in relief of neuropathic pain. Neurology 1998; 50: A255(abstract).
11. Jenson MG, Royal MA, Ward S, Movva V, Bhakta B, Gunyea I. Topiramate for the treatment of neuropathic and chronic pain syndromes: An open label trial. AJPM Am J Pain Manage 2002; 12: 12–16.
12. Misha-Miroslav B. Topiramate in the treatment of chronic neuropathic pain: A retrospective chart review. Ann Neurol 2001; 1: S63–S64(abstract).
13. Edwards KR, Glantz MJ, Button J, Norton JA, Whittaker T, Cross N, et al. Efficacy and safety of topiramate in the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled study. Neurology 2000; 54: A81(abstract).

One does not discover new lands without consenting to lose sight of the shore. - —André Gide